NCT03597009 - A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 6, 2019

Primary Completion Date

February 7, 2020

Study Completion Date

February 12, 2020

Conditions

Malignant Pleural EffusionStage IV Metastatic CancerLung Cancer

Interventions

DRUG

Talimogene laherparepvec (TVEC)

Talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles, with or without nivolumab

DRUG

Nivolumab

Nivolumab (240 mg IV) will be co-administered with talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles in the Dose Level 2 cohort

Trial Locations (1)

Lineberger Comprehensive Cancer Center, Chapel Hill